文献速递眼底病与葡萄膜炎

Vogt-小柳-原田病发病3个月内启动免疫调节治疗的研究

Vogt-Koyanagi-Harada Disease Managed With Immunomodulatory Therapy Within 3 Months of Disease Onset.
PubMed 文献 · Am J Ophthalmol · 2020-07-30

回顾性研究新加坡国家眼科中心2008-2018年29例(58眼)VKH患者,采用大剂量糖皮质激素并在3个月内加用免疫调节治疗(IMT)。与历史数据相比,视力结局更好且慢性复发性葡萄膜炎显著减少;6周内启动IMT者4年视力结局显著更优。

要点

  • VKH发病3个月内联合IMT可改善视力结局并降低慢性复发风险
  • 6周内启动IMT者4年视力显著优于6周后启动者
  • 58眼中58.6%出现晚霞状眼底,51.7%葡萄膜炎转为慢性

核心结论

  • 大剂量糖皮质激素联合3个月内启动IMT可改善视力结局并降低慢性复发性葡萄膜炎风险。
  • 6周内启动IMT者4年视力结局显著优于6周后启动者(P = .036)。
  • 与历史数据(葡萄膜炎未控制时才加用IMT)相比,3年视力结局显著更好(P = .04),慢性复发性疾病显著更少(P < .001)。

研究设计与样本

  • 回顾性干预性病例系列,纳入新加坡国家眼科中心2008-2018年VKH患者29例共58眼。
  • 标准化方案为静脉甲泼尼龙后接或不接口服泼尼松1 mg/kg每日缓慢减量,并在3个月内加用IMT。
  • 收集人口学、临床特征和吲哚菁绿血管造影(ICGA)数据,葡萄膜炎活动性经临床和ICGA评估。
  • 比较6周前与6周后(晚期IMT)启动IMT的结果,并与历史数据比较。

主要发现

  • 患者平均年龄42.2 ± 13.3岁,华人15例(51.7%)。
  • 晚霞状眼底发生于58眼中的34眼(58.6%)。
  • 葡萄膜炎消退24/58眼(41.4%),转为慢性30眼(51.7%),需处理慢性复发4眼(6.9%)。
  • 6周内启动IMT者4年视力结局显著更好(P = .036;Mann-Whitney U检验),晚霞状眼底和葡萄膜炎发生率相似。

关键数值与推荐

  • IMT启动时机分组标准:6周前 vs 6周后(晚期IMT)。
  • 历史对照为葡萄膜炎未控制时才加用IMT。
  • 视力结局比较时间点:4年(组内比较)和3年(与历史数据比较)。

临床怎么用

  • 对VKH患者可考虑在大剂量糖皮质激素基础上于发病3个月内早期加用IMT。
  • 6周内启动IMT可能与更好的长期视力结局相关。
  • 早期联合IMT可能降低慢性复发性葡萄膜炎的发生风险。

局限性

  • 回顾性病例系列设计。
  • 样本量较小(29例58眼)。
  • 与历史数据比较为非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To study the outcome of high-dose corticosteroids with early addition of immunomodulatory therapy (IMT) in patients with Vogt-Koyanagi-Harada (VKH) disease. DESIGN: Retrospective, interventional case series. METHODS: Patients with VKH seen at Singapore National Eye Centre from 2008-2018 were studied. The standardized clinical protocol was intravenous methyl prednisolone followed by/or oral prednisolone 1 mg/kg daily with slow taper plus IMT within 3 months. We collected data on demographics, clinical features, and indocyanine green angiography (ICGA). Uveitis activity was assessed clinically and by ICGA. Results were compared when IMT was given before vs after 6 weeks (late IMT) and with historical data (IMT added when uveitis uncontrolled). RESULTS: Fifty-eight eyes of 29 patients were studied. Half of the patients were Chinese (15, 51.7%). The mean age ± standard deviation was 42.2 ± 13.3 years. Twenty-five patients required 1 IMT and 4 needed 2 drugs. Sunset glow fundus occurred in 34 of 58 eyes (58.6%). Uveitis resolved in 24 of 58 eyes (41.4%), became chronic in 30 (51.7%), and required chronic recurrent in 4 eyes (6.9%). Eyes with IMT initiated within 6 weeks had better visual outcome that was significant at 4 years (P = .036; Mann-Whitney U test) but had a similar occurrence of sunset glow fundus and uveitis. Compared with historical data, visual outcome was better and was significant at 3 years (P = .04; t test), and significantly fewer patients developed chronic recurrent disease (P < .001; χ2 test). CONCLUSION: High-dose corticosteroids with IMT within 3 months resulted in improved visual outcomes and a reduced risk of developing chronic recurrent uveitis compared with IMT given as clinically indicated.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ei Ei Lin Oo, Chee SP, Wong KKY, et al. Vogt-Koyanagi-Harada Disease Managed With Immunomodulatory Therapy Within 3 Months of Disease Onset. Am J Ophthalmol. 2020. PMID: 32738228. doi:10.1016/j.ajo.2020.07.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。